Tag Archives: Matthew Herder

Enacting Pharmaceutical Transparency – Who, What, How, When, & Why

Matthew Herder shares a template letter that physicians, researchers, civil society groups, investigative journalists, and others can use to gain access to unpublished pharmaceutical safety and effectiveness data.

Testing Canada’s New Pharmaceutical Transparency Law

Matthew Herder and Trudo Lemmens explore the ways that Canada’s transparency legislation may limit researchers’ abilities to scrutinize drug safety and effectiveness.

Pharma Financialized

Matthew Herder argues that recent drug price hikes are only one part of a bigger problem with industry-driven pharmaceutical research and development.